Insights on Phase Appropriate GMP for Biological Processes: Pre-clinical to Commercial Production

PDA recently published a book on how to develop a biological drug product and, at the same time, stay within the regulatory expectations at each phase of the development process. RCA’s Sue Schniepp authored Chapter 8: Deviations, Change Control, Process Improvements. Other chapters include:

 

  • Current manufacturing and process development of Regenerative Medicine Advanced Therapy Products (RMATs), or as they are known in the EU, Advanced Therapy Medicinal Products (ATMPs)
  • Quality systems and GMP requirements for Phase 1 to Phase 3 manufacturing
  • The impact of the Clinical Trials Directive on European GMP expectations and the role of the QP
  • The latest USP guidance on the transfer of analytical methods, validation and verification of compendial procedures
  • And, much more

I'm Interested in Learning More About RCA

*=Required

News

Susan Schniepp Makes Impression With Talk About Quality Culture in Berlin...
Read More

News

Susan Schniepp Makes Impression With Talk About Quality Culture in Berlin...
Read More

News

Susan Schniepp Makes Impression With Talk About Quality Culture in Berlin...
Read More
Insights on Phase Appropriate GMP for Biological Processes: Pre-clinical to Commercial Production...
Read More
PDA Midwest Chapter – Regulatory Submissions & Changes...
Read More